A phase II study of CORT-118335 for Non-alcoholic-fatty-liver-disease

Trial Profile

A phase II study of CORT-118335 for Non-alcoholic-fatty-liver-disease

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs CORT 118335 (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 New trial record
    • 02 Nov 2017 According to a Corcept Therapeutics media release, the company plans to initiate this trial in the third quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top